Beth Hecht Sells 16,666 Shares of Xeris Biopharma (NASDAQ:XERS) Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Beth Hecht sold 16,666 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $8.49, for a total value of $141,494.34. Following the transaction, the insider directly owned 1,127,796 shares in the company, valued at approximately $9,574,988.04. This represents a 1.46% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Beth Hecht also recently made the following trade(s):

• On Monday, August 3rd, Beth Hecht sold 16,666 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.01, for a total value of $133,494.66.
• On Wednesday, July 1st, Beth Hecht sold 16,666 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.03, for a total value of $133,827.98.

Xeris Biopharma Price Performance

Xeris Biopharma stock opened at $8.58 on Thursday. Xeris Biopharma Holdings, Inc. has a 12 month low of $5.25 and a 12 month high of $10.08. The company has a debt-to-equity ratio of 17.00, a current ratio of 1.45 and a quick ratio of 1.02. The business has a 50 day simple moving average of $8.37 and a 200-day simple moving average of $6.96. The stock has a market capitalization of $1.56 billion, a PE ratio of -78.00 and a beta of 0.70.

Xeris Biopharma (NASDAQ:XERS) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.19). The firm had revenue of $92.10 million during the quarter, compared to analysts’ expectations of $90.12 million. Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. Equities analysts predict that Xeris Biopharma Holdings, Inc. will post 0.07 earnings per share for the current year.

Institutional Investors Weigh In On Xeris Biopharma

Several institutional investors have recently modified their holdings of XERS. Allianz Asset Management GmbH purchased a new position in Xeris Biopharma in the 2nd quarter valued at approximately $314,000. Corient Private Wealth LP acquired a new stake in Xeris Biopharma in the second quarter valued at $1,458,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Xeris Biopharma in the second quarter valued at $89,000. California State Teachers Retirement System raised its stake in shares of Xeris Biopharma by 720.4% during the 2nd quarter. California State Teachers Retirement System now owns 1,479,456 shares of the company’s stock worth $11,717,000 after buying an additional 1,299,117 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Xeris Biopharma by 2.9% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 687,632 shares of the company’s stock worth $5,446,000 after buying an additional 19,558 shares during the last quarter. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on XERS. Barclays increased their price target on shares of Xeris Biopharma from $9.00 to $12.00 and gave the stock an “overweight” rating in a report on Thursday, August 20th. Weiss Ratings lowered Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Finally, Wall Street Zen downgraded Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Three equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Xeris Biopharma has a consensus rating of “Hold” and a consensus price target of $12.00.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.